Looking At CRISPR Therapeutics's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics CRSP, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CRSP usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for CRISPR Therapeutics. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 2 are puts, totaling $98,000, and 9 are calls, amounting to $744,659.

Expected Price Movements

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $90.0 for CRISPR Therapeutics, spanning the last three months.

Analyzing Volume & Open Interest

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 1260.1 with a total volume of 1,027.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $55.0 to $90.0 over the last 30 days.

CRISPR Therapeutics Call and Put Volume: 30-Day Overview

Noteworthy Options Activity:

About CRISPR Therapeutics

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Having examined the options trading patterns of CRISPR Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Where Is CRISPR Therapeutics Standing Right Now?

• With a volume of 2,279,956, the price of CRSP is up 0.86% at $61.12.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 60 days.

What Analysts Are Saying About CRISPR Therapeutics

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $78.0.

• Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $57.
• In a cautious move, an analyst from Mizuho downgraded its rating to Buy, setting a price target of $82.
• Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on CRISPR Therapeutics with a target price of $160.
• Reflecting concerns, an analyst from TD Cowen lowers its rating to Underperform with a new price target of $30.
• Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for CRISPR Therapeutics, targeting a price of $61.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CRISPR Therapeutics options trades with real-time alerts from Benzinga Pro.